AbbVie to present new drug data at EULAR 2015

AbbVie has announced that it will be presenting data from more than 30 abstracts at the European League Against Rheumatism (EULAR) Annual Congress.

The event in Rome runs from June 10th to 13th and will see the company present over 20 abstracts on its blockbuster drug Humira, detailing its performance in approved indications, as well as in an investigational application as a therapy for non-infectious intermediate, posterior or panuveitis.

Data evaluating four investigational medicines will also be presented, including the new compounds ABT-122 and ABT-981, which were developed using AbbVie's proprietary DVD-IG technology.

Additionally, insights into the real-world impact of rheumatologic diseases will be shared, as well as new research on the company's investigational medicines for rheumatoid arthritis, knee osteoarthritis and lupus.

Dr Scott Brun, vice-president for pharmaceutical development at AbbVie, said: "AbbVie's presence at EULAR showcases our ongoing commitment to elevating the quality of care for people living with serious inflammatory diseases around the world."

The firm attended the annual meeting of the American Society of Clinical Oncology earlier this week, where it presented new data assessing venetoclax as a treatment for multiple myeloma.